Optimi Health Corp. OPTH
2.30 USD -0.10 (-4.17%)
Nov 12, 2026, 12:47 PM EST
2.05 Day range 2.34
1.90 52-week range 6.40
- YTD
- -62.17%
- 1 year
- -62.17%
News
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…
benzinga.com Optimi Health Completes Latest Production Batch Of Its MDMA Finished Drug Product; Proposed Phase 3 Trial Expected To Begin In 2027 The capsules were manufactured at Optimi’s GMP facility in Princeton, British Columbia, under its Health Canada Drug Establishment Licence, and are expected to supply three programs: the recently…
benzinga.com Optimi Health Completes Production Batch Of 5mg Naturally Derived Psilocybin Capsules, Manufactured End To End At cGMP Facility In Princeton, British Columbia Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the…
benzinga.com Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial As Elon Musk touts psychedelics for mental health and the FDA holds hearings, Optimi Health (OPTH) supplies commercial MDMA & psilocybin.
benzinga.com Optimi Health Plans To Initiate A Phase 3 Clinical Trial Evaluating MDMA-Assisted Therapy For PTSD Authorized By Health Canada; Trial Is Expected To Begin In 2027 The Phase 3 clinical trial is intended to enroll up to 100 participants across multiple sites in Canada, with enrollment focused on veterans and current or former frontline workers, including…- benzinga.com Optimi Health Plans To Initiate Multisite Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy For Individuals With Major Depressive Disorder In H1 2027, With Dosing Expected To Be Complete By 2027 End Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027Up to 200 participants at sites across Canada, among…
- benzinga.com Optimi Health Exports Third Shipment Of Its 5Mg Psilocybin Product To Australia Since September 2025 The shipment included 1,000 capsules of 5mg psilocybin, which are being prescribed in Australia for treatment-resistant depression ("TRD"), an indication for which regulated patient access is…
benzinga.com Optimi Health Completes Production Of Two Microdose Psilocybin Finished Drug Products, Formulated At 1 Mg And 2 Mg Dosages; Products Available To Authorized Clinical Research Organizations Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studiesNew microdose formats extend Optimi's…- benzinga.com Optimi Health Prices Underwritten Public Offering Of 2.40M Common Shares At $6.25/Shr Common Shares to Trade on the Nasdaq Capital Market Under the Symbol "OPTH"VANCOUVER, BC, May 20, 2026 /CNW/ - Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a…